Insight into CGI’s Molecular Diagnostics Work in India

Written by: Anna Israyelyan, MD, PhD
Manager, Biopharma Solutions

Published on:
February 8th, 2017

Anna Israyelyan, MD, PhD
Dr. Israyelyan joined CGI in 2015. She has over 15 years of extensive cancer research and management experience in industry and academia covering wide range of medical areas, including basic, translational, and clinical research. Anna is an active member of the American Society of Hematology (ASH), the American Association for Cancer Research (AACR), and American Association for the Advancement of Science (AAAS). Dr. Israyelyan has a scientific advisory role with matrix management of scientific, technical, and operational aspects related to various biopharma projects and collaborations involving biomarkers in solid tumors and hematologic malignancies.

Based in Hyderabad, CG India (previously BioServe India, now a CGI Company) offers Indian scientists, pharmaceutical companies, and research institutes a full suite of molecular services and research tools to accelerate breakthroughs in genetics, drug discovery, biomarker research, and molecular diagnostics.

CG India’s customers include nearly every Indian Council of Medical Research (ICMR) and Council for Scientific and Industrial Research (CSIR) institute, as well as several major pharmaceutical and biotechnology companies. As with our U.S. collaborations, CG India’s many partnerships and agreements are directed towards continuing broadening the access to our unique, proprietary portfolio of genomic and biomarker driven tests, which help in the management of patient care improving outcomes throughout India and broader Asia.

This month, we’ll be presenting at two important conferences in India, where CGI experts will share their insights on the journey of personalized medicine with a focus on oncology. Specifically, our talks will focus on the rapid adaptation and validation of diagnostic assays reported by clinical laboratories and the expanding role of pathologists in interpreting molecular and histopathological features of solid tumors, thus making tailored cancer treatments (including novel immunotherapies) for individual patients possible. Additionally, our presentations will cover another emerging area in precision medicine – liquid biopsy. Our presentation discusses how circulating / cell-free DNA analysis provides a more complete and precise picture of the patient’s tumor, than a single tissue-based biopsy.

The 6th Annual Conference of the Molecular Pathology Association of India (MPAI) is set for 10th and 11th of February 2017 at the Kalinga Institute of Industrial Technology (KIIT) in Bhubaneswar, India. The focus of the conference is the molecular diagnosis and prognosis of solid tumors, hematological oncology, infectious diseases and genetic diseases utilizing traditional and novel DNA- and RNA-based technologies, including next generation sequencing (NGS) and digital PCR. CGI experts will introduce a series of case studies to showcase how the integration of cancer genomics and pathology in clinical services assists in better treatment regimens for oncology patients.

Next, CG India and Centre for Cellular & Molecular Biology (CCMB) are jointly organizing the 2nd Annual NGS Conference scheduled to take place from 22nd to 24th of February 2017 in Hyderabad, India. The objective is to provide recent updates on NGS technologies, including applications across various disciplines beyond oncology.

 CG India professionals at the 1st Annual NGS Conference in India


If you’re interested in attending – or simply learning more about CG India, please drop me a note.

Anna Israyelyan, MD, PhD
Clinical Affairs Manager
Anna.Israyelyan@cgix.com
Tel: 323.224.3900 x175

You can also connect with me on LinkedIn.

Comments

comments